TaiGen in strategic agreement with Procter & Gamble

Published: 7-Jan-2005

TaiGen Biotechnology has signed a strategic alliance with Procter & Gamble Pharmaceuticals (P&GP) to further the development and commercialisation of a novel non-fluorinated quinolone antibiotic, invented by P&GP.


TaiGen Biotechnology has signed a strategic alliance with Procter & Gamble Pharmaceuticals (P&GP) to further the development and commercialisation of a novel non-fluorinated quinolone antibiotic, invented by P&GP.

Under the terms of the agreement, TaiGen will be responsible for conducting Phase Ib and Phase II development of the compound. If Phase II results are positive P&G, in conjunction with TaiGen, may then seek a pharmaceutical partner for the Phase III development and subsequent commercialisation.

The agreement also entitles TaiGen to development and commercialisation rights within China, Taiwan, Korea and the ASEAN countries.

  

You may also like